Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Evofem Biosciences Inc

Infinity Pharma

With biotech penny stocks heating up, here are 3 you need to know about in August The post Best Biotech Penny Stocks For Your Monday Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks For Your Monday Watchlist

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that Steven Quay, M.D., Ph.D., Atossa's President and CEO, and Kyle Guse, Atossa's Chief Financial Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9-10, 2021.

Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021

Investors have become wary of the risks surrounding Atossa's pipeline. That caution will continue pulling down ATOS stock The post The Bear Case for Atossa Therapeutics Makes More Sense at This Time appeared first on InvestorPlace.

The Bear Case for Atossa Therapeutics Makes More Sense at This Time

Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point. The post Investors Should Avoid High-Risk Atossa Therapeutics appeared first on InvestorPlace.

Investors Should Avoid High-Risk Atossa Therapeutics

ATOS stock is on its way down today. As the biotech company announces a special shareholder meeting, holders worry about stock dilution.

ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today

The potential with its breast cancer and Covid-19 treatment candidates notwithstanding, don't fight the trend with ATOS stock. The post Wait for Atossa Therapeutics Stock to Slide Further Before Buying appeared first on InvestorPlace.

Wait for Atossa Therapeutics Stock to Slide Further Before Buying

ATOS stock is a relatively unknown pharmaceutical firm that is worth keeping an eye on due to surging Covid-19 cases. The post Atossa Therapeutics Might Shoot Up Quickly on Covid-19 Fear appeared first on InvestorPlace.

Atossa Therapeutics Might Shoot Up Quickly on Covid-19 Fear

ATOS stock attracted social media for its possible short-squeeze play and its therapeutic offerings but speculators should be careful. The post Think Carefully Before Speculating on Atossa Therapeutics appeared first on InvestorPlace.

Think Carefully Before Speculating on Atossa Therapeutics

SEATTLE, July 26, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay and a group of international scientists have published a pre-print, available here, entitled, "CONTAMINATION OR VACCINE RESEARCH? RNA Sequencing data of early COVID-19 patient samples show abnormal presence of vectorized H7N9 hemagglutinin segment.

Physician-Scientist Steven Quay: Forensic examination of Wuhan Institute of Virology COVID-19 patient specimens from December 2019 reveals extensive laboratory contamination, including evidence of genetic manipulation of the Nipah Virus, a BSL-4 pathogen 

Vinco Ventures

Cinedigm

Reddit penny stocks are heating up right now; here's 3 to watch The post 3 Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Are Popular on Reddit Right Now

After a steep selloff, shares of Atossa Therapeutics, Inc. (NASDAQ: ATOS) have reached the critical $4 level. This level was support in early June.

Is Atossa Therapeutics Stock Breaking Important Support?

Traders will continue to analyze the short-squeeze potential of ATOS stock, but investors should also focus on Atossa's clinical progress. The post A Promising Covid-19 Treatment Makes Atossa Therapeutics Intriguing appeared first on InvestorPlace.

A Promising Covid-19 Treatment Makes Atossa Therapeutics Intriguing

SEATTLE, July 15, 2021 /PRNewswire/ -- An international team of scientists and data analysts, led by Physician-Scientist Steven Quay, MD, PhD, has published a paper entitled, "Science Not Speculation Should Inform the Investigation of the Origin of COVID-19," in which they conclude: "Until new evidence is found, an investigation of the pathway for the origin of COVID-19 should proceed with the assumption that a laboratory-acquired infection or research-related accident is at least as likely, if not more likely, than a natural zoonotic transmission." The paper was submitted to the Subcommittee on Investigations and Oversight hearing, Principles for Outbreak Investigation: COVID-19 and Future Infectious Diseases," held on July 14, 2021.

Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress

Atossa Therapeutics Inc (NASDAQ: ATOS) shares are trading higher Tuesday after retail traders were able to push the stock higher. The stock was trading on above-average volume Tuesday and was trending on social media sites throughout the day such as StockTwits.

Atossa Therapeutics Stock Runs While Trading In Bearish Pattern

Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease

Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

The Reddit crowd might decide to target ATOS stock for a short squeeze, but that's not the only reason to take a long position today. The post The Bulls Are in Charge of Atossa Therapeutics appeared first on InvestorPlace.

The Bulls Are in Charge of Atossa Therapeutics

Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.

Can Atossa Therapeutics Stock Keep Climbing?

The stock price of Atossa Therapeutics Inc (NASDAQ: ATOS) increased 10.77%. This is why it happened.

ATOS Stock Price Increased 10.77%: Why It Happened

The Seeking Alpha Quant System alerted Premium users of this hidden stock, and in a month the stock prices shot up 120%. This stock carries a short interest of 11%. If the company continues to do well, then the stock could see more significant upside as the shorts cover.

Quant System Highlight: Investors Following This Are Up 120% In A Month! (Video)

Today, ATOS stock is on the move as a range of catalysts appear to be lining up perfectly for retail investors in this Reddit favorite. The post ATOS Stock: How Redditors and a June 28 Catalyst Are Squeezing Atossa Therapeutics appeared first on InvestorPlace.

ATOS Stock: How Redditors and a June 28 Catalyst Are Squeezing Atossa Therapeutics

Retail traders hyped Atossa Therapeutics on Reddit's penny stocks thread, saying it's on track to rocket.

A tiny biotech company focused on breast cancer treatments has soared 29% amid Reddit hype

There are two likely drivers behind the biotech's share price surge.

Why Atossa Therapeutics Stock Is Jumping Today

The stock price of Atossa Therapeutics Inc (NASDAQ: ATOS) increased by over 4% pre-market. This is why it happened.

ATOS Stock Price Increases Over 4% Pre-Market: Why It Happened

The stock price of Atossa Therapeutics, Inc. (Nasdaq: ATOS) increased by 10.54% yesterday. This is why it happened.

ATOS Stock Price Increased 10.54%: Why It Happened

SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced it is set to be added to the Russell 2000 and Russell 3000 Indexes This milestone will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, and June 14, 2021.

News for Atossa Genetics Stock (ATOS)